Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
- Vanda Pharmaceuticals narrows 2024 revenue view to $190M-$210M from $180M-$210M
- Vanda Pharmaceuticals reports Q3 EPS (9c), consensus (16c)
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Vanda Pharmaceuticals initiated with a Buy at H.C. Wainwright